State Street SPDR S&P Biotech ETF
XBI
414 hedge funds and large institutions have $5.13B invested in State Street SPDR S&P Biotech ETF in 2018 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 146 increasing their positions, 119 reducing their positions, and 45 closing their positions.
53% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 45
32% more capital invested
Capital invested by funds: $3.88B → $5.13B (+$1.25B)
23% more repeat investments, than reductions
Existing positions increased: 146 | Existing positions reduced: 119
12% more funds holding in top 10
Funds holding in top 10: 17 → 19 (+2)
10.15% more ownership
Funds ownership: 96.2% → 106.36% (+10%)
4% more funds holding
Funds holding: 397 → 414 (+17)
57% less call options, than puts
Call options by funds: $691M | Put options by funds: $1.62B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$472M |
| 2 |
Morgan Stanley
New York
|
+$189M |
| 3 |
Goldman Sachs
New York
|
+$162M |
| 4 |
Rafferty Asset Management
New York
|
+$126M |
| 5 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$123M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AssetMark Inc
Concord,
California
|
-$72.9M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$67.8M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$48.6M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$23.1M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.6M |
XBI Hedge Fund Activity: Q1 2018 in Review
414 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2018, worth a combined $5.13B — up 32% from $3.88B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new XBI positions and 45 closed out — a net gain of 24 holders — while 146 added to existing stakes and 119 trimmed.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $472M. The largest seller was AssetMark Inc, cutting an estimated $72.9M.
- 414 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2018, up from 397 in Q4 2017.
- Funds reported $5.13B of State Street SPDR S&P Biotech ETF stock for Q1 2018, up 32% quarter-over-quarter.
- 69 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2018 and 45 closed out, a net change of +24 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q1 2018 was Deutsche Bank, an estimated $472M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q1 2018 was AssetMark Inc, an estimated $72.9M sold.
Based on aggregated 13F filings for Q1 2018.